- The latest acquisition expands the group's new economy real estate territory to the life sciences.
- The business park is strategically located in the core biopharmaceutical R & D cluster in China.
- ESR Cayman LimitedHas established more than one of China's major biomedical industry clusters.5010,000 square meters of life science real estate project reserve
Singapore and Hong KongAugust 11, 2022/ PR Newswire /-ESR Cayman Limited Group Limited, the largest real estate management company in the Asia-Pacific region driven by the new economy ("ESR Cayman Limited”Or "company"”, together with its subsidiaries, are collectively referred to as the "group"”Hong Kong Stock Exchange Stock Code: 1821) ushered in a strategic milestone to enter China's most famous biopharmaceutical R & D cluster.
ESR Cayman Limited and his partners bought the life science R & D industrial park in Zhangjiang, Shanghai, for 268 million yuan ($40 million). The life science R & D industrial park, formerly known as Zhangjiang NEO, is located in Shanghai Zhangjiang High-tech Development Park (Zhangjiang Pharmaceutical Valley Phase II). The area is a leading life science industrial cluster with more than 600 life science companies, 150 R & D institutions and 7 of the world's top 10 pharmaceutical companies. The strategic location of the industrial park also enables it to quickly link Shanghai's central business district, major hubs and public transport facilities and airports. Zhangjiang NEO has a total floor area of 8940 square meters and consists of two pharmaceutical R & D laboratories and office space with four to five floors. More than 90% of tenants (in terms of leased floor area) are leading biomedical companies focusing on innovative drug research and development in oncology, immunity, and other diseases with significant unmet medical needs, covering large and small molecules, and provide solutions for raw materials and technologies in the related life sciences.
ESR Cayman Limited co-founder and co-CEO Shen Jinchu and Stuart Gibson said, "We are pleased to expand the new economy real estate landscape to the life sciences and further expand the scope of ESR Cayman Limited's real estate investment solution. As the largest new economy real estate platform in the Asia-Pacific region, we are working to meet the growing needs of the biopharmaceutical industry to meet the health care needs of China and the Asia-Pacific region as a whole. We will take advantage of our core competitive advantages to provide innovative products and operational models, such as shared laboratories, to meet the R & D needs of pharmaceutical companies. With our strong land expansion capabilities, first-class design and construction capabilities, integrated fund management platform and commitment to sustainable development-we are well positioned to support the vigorous development of our capital partners and customers, grasp the long-term development trend of the life science industry.”
By 2020, Zhangjiang accounts for 15% of the global market share of newly developed original research drugs, and is expected to become a world-class biopharmaceutical innovation and production industry cluster.[1]. With the strong development momentum of technological and industrial innovation, China's pharmaceutical and life sciences industry has grown rapidly in recent years, and the novel coronavirus epidemic in 2020 has provided a greater impetus for the expansion of the industry.
China has become the world's largest exporter of API and the world's second largest pharmaceutical market.[2]. Driven by the reform of the central government's medical insurance and modern hospital system, and against the backdrop of the growing and aging urban population's increasing demand for quality health care, China's biotechnology and pharmaceutical market is expected to continue to expand rapidly, leading to a rapid increase in demand for life science real estate from a wide range of industry participants, such as pharmaceutical companies, drug distribution companies and research and development institutions.
资Data sources:¹,² Drug Evaluation Center of the State Drug Administration[Huoshi]Shanghai Economic and Information CommissionCBREResearch-2021In the second quarter of 2008.
AboutESR Cayman Limited
ESR Cayman Limited is the largest real estate management company in the Asia-Pacific region driven by the new economy, and the third largest listed real estate investment management company in the world, with total assets under management of US $140.2 billion. We have built a fully integrated development and investment management platform, covering major markets in the Asia-Pacific region, including China, Japan, South Korea, Australia, Singapore, India, New Zealand and Southeast Asia, accounting for more than 95% of the GDP of the Asia-Pacific region. it is also expanding its business coverage in Europe and the United States. Through our private equity business, we provide comprehensive real estate investment solutions and new economy real estate development opportunities to enable capital partners and customers to grasp the main long-term trends in the Asia-Pacific region. ESR Cayman Limited is the largest REITs sponsor and manager in the Asia-Pacific region, with a total asset management of US $45 billion. Our tenet ──Space and Investment Scheme for Sustainable Future─ promotes sustainable and influential management and regards the environment and the community in which we operate as the main stakeholders of our business. ESR Cayman Limited is listed on the main board of the Stock Exchange of Hong Kong and is now a member of the FTSE global stock index series (large stocks), the Hang Seng Composite Index and the MSCI Hong Kong Index. For more information about ESR Cayman Limited, please visit the website.